medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-4-14-19medsovet-3109Research ArticleСАХАРНЫЙ ДИАБЕТDIABETES MELLITUSСитаглиптин - первый в мире ингибитор ДПП-4Sitagliptin: the world’s first DPP-4 inhibitorПетунинаН. А.PetuninaN. A.

Петунина Нина Александровна - доктор медицинских наук, профессор, заведующая кафедрой эндокринологии Института клинической медицины.

Москва, 119991, Трубецкая, д. 8, стр. 2; тел.: 8-495530-32-16, eLibrary SPIN-код 9784-3616

Petunina Nina Aleksandrovna - Dr. of Sci. (Med.), Professor, Head of Chair for Endocrinology, Clinical Medicine Institute, Federal State Autonomous Educational Institute of Higher Education.

Moscow, 119991, Trubetskaya St., 8, Bldg. 2, Work Phone: 8-495-530-32-16, eLibrary SPIN-code 97843616

napetunina@mail.ruГончароваЕ. В.GoncharovaE. V.

Гончарова Екатерина Валерьевна - кандидат медицинских наук, доцент кафедры эндокринологии Института клинической медицины.

Москва, 119991, Трубецкая, д. 8, стр. 2; тел.: 8-495-530-33-13, eLibrarySPIN-код 71484669

Goncharova Ekaterina Valerievna - Cand. of Sci. (Med.), Assistant Professor of Chair for Endocrinology, Clinical Medicine Institute, Federal State Autonomous Educational Institute of Higher Education.

Moscow, 119991, Trubetskaya St., 8, Bldg. 2, Work Phone: 8-495-530-33-13, eLibrary SPIN-code 7148-4669

goncharova_ev@inbox.ruТельноваМ. Э.TelnovaM. E.

Тельнова Милена Эдуардовна - кандидат медицинских наук, доцент кафедры эндокринологии Института клинической медицины.

Москва, 119991, Трубецкая, д. 8, стр. 2; тел.: 8-495-530-3313, eLibrary SPIN-код 1007-4617

Telnova Milena Eduardovna - Cand. of Sci. (Med.), Assistant Professor of Chair for Endocrinology, Clinical Medicine Institute, Federal State Autonomous Educational Institute of Higher Education.

Moscow, 119991, Trubetskaya St., 8, Bldg. 2, Work Phone: 8-495-530-33-13, eLibrary SPIN-code 1007-4617

milena.telnova@mail.ruТрухинаЛ. В.TrukhinaL. V.

Трухина Любовь Валентиновна - кандидат медицинских наук, доцент кафедры эндокринологии Института клинической медицины.

Москва, 119991, Трубецкая, д. 8, стр. 2; тел.: 8-495530-33-13, eLibrary SPIN-код 2388-3053

Trukhina Lyubov Valentinovna - Cand. of Sci. (Med.), Assistant Professor of Chair for Endocrinology, Clinical Medicine Institute, Federal State Autonomous Educational Institute of Higher Education.

Moscow, 119991, Trubetskaya St., 8, Bldg. 2, Work Phone: 8-495-530-33-13, eLibrary SPIN-code 2388-3053

lvtruhina@gmail.comМартиросянН. С.MartirosyanN. S.

Мартиросян Нарине Степановна - кандидат медицинских наук, ассистент кафедры эндокринологии Института клинической медицины.

Москва, 119991, Трубецкая, д. 8, стр. 2; тел.: 8-495530-33-13, eLibrary SPIN-код 1893-8030

Martirosyan Narine Stepanovna - Cand. of Sci. (Med.), Assistant Professor of Chair for Endocrinology, Clinical Medicine Institute, Federal State Autonomous Educational Institute of Higher Education.

Moscow, 119991, Trubetskaya St., 8, Bldg. 2, Work Phone: 8-495-530-33-13, eLibrary SPIN-code 1893-8030

narinarine@list.ruФедеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation201919082019041419Copyright © Петунина Н.А., Гончарова Е.В., Тельнова М.Э., Трухина Л.В., Мартиросян Н.С., 20192019Петунина Н.А., Гончарова Е.В., Тельнова М.Э., Трухина Л.В., Мартиросян Н.С.Petunina N.A., Goncharova E.V., Telnova M.E., Trukhina L.V., Martirosyan N.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/3109

Ежегодный рост распространенности СД2 привел к активным поискам управления заболеванием. В последнее десятилетие появились новые группы сахароснижающих препаратов, которые не только оказались эффективными в коррекции гипергликемии, безопасными в отношении гипогликемий, но и вошли в число препаратов первой линии терапии. Среди них средства с инкретиновой активностью - ингибиторы дипептидилпептидазы 4-го типа (иДПП-4, глиптины). Ситаглиптин был первым в мире утвержденным иДПП-4 и уже с 2007 г. начал успешно применяться в России. В обзоре представлены данные по эффективности, безопасности (в т. ч. кардиобезопасности) применения ситаглиптина и накопившийся опыт его применения в терапии пациентов с СД2.

The prevalence of T2D is steadily increasing annually, which resulted in an active search for a way to control the disease. The last decade has seen a rise in the number of new groups of glucose-lowering drugs, which not only proved effective in the management of hyperglycemia and safe against hypoglycemia, but also joined the ranks of the drugs of the first-line therapy. Among them is incretin-active agents - type 4 dipeptidyl peptidases inhibitors (IDPP-4, glyptines). Sitagliptin was the world's first approved IDPP-4, and began to be used successfully in Russia since 2007. The review presents data on the efficacy, safety (including cardiac safety) of sitagliptin use and accumulated experience of its use in the treatment of patients with type 2 diabetes.

глиптиныиДПП-4ситаглиптинсахарный диабет 2-го типаTECOSgliptinsDPP-4sitagliptindiabetes mellitusT2DMTECOSReferencesDiabetes Atlas 8ed. international Diabetes Federation, 2017. Online version of IDF Diabetes Atlas. www.diabetesatlas.org.Diabetes Atlas 8ed. international Diabetes Federation, 2017. Online version of IDF Diabetes Atlas. www.diabetesatlas.org.Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. Вып. 8. Сахарный диабет. 2017;20(1S):1-112.Algorithms of Specialized Medical Care for Diab etes Mellitus Patients. Under the editorship of i.i. Dedov, M.V. Shestakov, A.Yu. Mayorov, issue 8. Sakhamy Diabet. 2017;20(1S):1-112. (in Russ).Lankas G.R., Leiting B., Roy R.S., Eiermann GJ., Beconi M.G., Biftu T. et al. Dipeptidyl peptidase iV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005;54:2988-2994.Lankas G.R., Leiting B., Roy R.S., Eiermann GJ., Beconi M.G., Biftu T. et al. Dipeptidyl peptidase iV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005;54:2988-2994.Петунина Н.А., Гончарова Е.В., Потапова С.А. Кардиоваскулярная безопасность глиптинов: акцент на алоглиптин. Медицинский совет. 2017;3:32-37.Petunina N.A., Goncharova E.V., Potapova S.A. Cardiovascular safety of glyptins: focus on alogliptin. Meditsinskij Sovet. 2017;3:32-37. (in Russ).Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes preclinical biology and mechanisms of action. Diabetes Care. 2007;30:1335-1343.Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes preclinical biology and mechanisms of action. Diabetes Care. 2007;30:1335-1343.Lamers D., Famulla S., Wronkowitz N., Hartwig S., Lehr S., Ouwens D.M. et aL Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60:1917-1925.Lamers D., Famulla S., Wronkowitz N., Hartwig S., Lehr S., Ouwens D.M. et aL Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60:1917-1925.Ruter J., Hoffmann T., Demuth H.U., Moschansky P, Klapp B.F., Hildebrandt M. Evidence for an interaction between leptin, T cell costimulatory antigens CD28, CTLA-4 and CD26 (dipeptidyl peptidase iV) in BCG-induced immune responses of leptin- and leptin receptor-deficient mice. Biol Chem. 2004;385:537-541.Ruter J., Hoffmann T., Demuth H.U., Moschansky P, Klapp B.F., Hildebrandt M. Evidence for an interaction between leptin, T cell costimulatory antigens CD28, CTLA-4 and CD26 (dipeptidyl peptidase iV) in BCG-induced immune responses of leptin- and leptin receptor-deficient mice. Biol Chem. 2004;385:537-541.Aso Y., Terasawa T., Kato K., Jojima T., Suzuki K., iijima T., Kawagoe Y., Mikami S., Kubota Y., inukai T., Kasai K. The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. Transl Res. 2013;162:309-316.Aso Y., Terasawa T., Kato K., Jojima T., Suzuki K., iijima T., Kawagoe Y., Mikami S., Kubota Y., inukai T., Kasai K. The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. Transl Res. 2013;162:309-316.Петунина НА.,Трухина Л.В., Гончарова Е.В. Роль вилдаглиптина в оптимизации гликеми-ческого контроля. Справочник поликлинического врача. 2012;09:46-49.Petunina N.A., Trukhina L. V., Goncharova E.V. Role of vildagliptin in optimizing glycemic control. Spravochnik Poliklini-cheskogo Vracha. 2012;09:46-49. (In Russ).Bergman AJ., Stevens C., Zhou Y., Yi B., Laethem M. , De Smet M. et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers. Clinical Therapeutics. 2O06 January; 28(1):55-72.Bergman AJ., Stevens C., Zhou Y., Yi B., Laethem M. , De Smet M. et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers. Clinical Therapeutics. 2O06 January; 28(1):55-72.Herman G.A., Bergman A., Stevens C., Katy P.,Yi B., Zhao P. et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9.Herman G.A., Bergman A., Stevens C., Katy P.,Yi B., Zhao P. et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9.Miller S., St Onge E.L. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother. 2006 Jul-Aug;40(7-8):1336-43.Miller S., St Onge E.L. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother. 2006 Jul-Aug;40(7-8):1336-43.Петунина НА, Гончарова Е.В., Терехова А.Л. Управление сахарным диабетом. Новая эпоха самоконтроля: выявление тенденций и закономерностей гликемии. Сахарный диабет. 2017; 20(6):441-448.Petunina N.A., Goncharova E.V, Terekhova A.L. Diabetes Management. A new era of self-control: identifying trends and patterns of glyce-mia. Sakharny Diabet. 2017;20(6):441-448. (In Russ).Chan J.C., Scott R., Arjona Ferreira J.C., Sheng D., Gonzalez E., Davies MJ. et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008 Jul;10(7):545-55.Chan J.C., Scott R., Arjona Ferreira J.C., Sheng D., Gonzalez E., Davies MJ. et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008 Jul;10(7):545-55.Scott R., Morgan G., Zimmer Z. Lam R.L.H., O’Neill E.A., Kauffman K.D. et al. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes Obes Metab. 2018;1-9.Scott R., Morgan G., Zimmer Z. Lam R.L.H., O’Neill E.A., Kauffman K.D. et al. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes Obes Metab. 2018;1-9.Gomez N., Touihri K., Matheeussen V., Mendes Da Costa A., Mahmoudabady M., Mathieu M. et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail. 2012;14(1):14-21.Gomez N., Touihri K., Matheeussen V., Mendes Da Costa A., Mahmoudabady M., Mathieu M. et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail. 2012;14(1):14-21.Read P.A., Khan F.Z., Heck P.M., Hoole S.P., Dutka D.P. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3(2):195-201.Read P.A., Khan F.Z., Heck P.M., Hoole S.P., Dutka D.P. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3(2):195-201.Hibuse T., Maeda N., Kishida K., Kimura T., Minami T., Takeshita E. et al. A pilot 3-month sit-agliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus - a randomized controlled trial START-J study. Cardiovasc Diabetol. 2014;13:96.Hibuse T., Maeda N., Kishida K., Kimura T., Minami T., Takeshita E. et al. A pilot 3-month sit-agliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus - a randomized controlled trial START-J study. Cardiovasc Diabetol. 2014;13:96.Eurich D.T., Weir D.L., Simpson S.H., Senthilselvan A., McAlister F.A. Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study. Diabet Med. 2016 May;33(5):621-30.Eurich D.T., Weir D.L., Simpson S.H., Senthilselvan A., McAlister F.A. Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study. Diabet Med. 2016 May;33(5):621-30.Nakamura K., Oe H., Kihara H., Shimada K., Fukuda S., Watanabe K., Takagi T. et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol. 2014;13:110.Nakamura K., Oe H., Kihara H., Shimada K., Fukuda S., Watanabe K., Takagi T. et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol. 2014;13:110.Leibovitz E., Gottlieb S., Goldenberg I., Gevrielov-Yusim N., Matetzky S., Gavish D. Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS). Cardiovasc Diabetol. 2013;12:53.Leibovitz E., Gottlieb S., Goldenberg I., Gevrielov-Yusim N., Matetzky S., Gavish D. Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS). Cardiovasc Diabetol. 2013;12:53.Green J.B., Bethel M.A., Armstrong P. W., Buse J.B., Engel S.S. et al.Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373:232-242.Green J.B., Bethel M.A., Armstrong P. W., Buse J.B., Engel S.S. et al.Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373:232-242.Engel S.S., Golm G.T., Shapiro D., Davies MJ., Kaufman K.D., Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol. 2013;12:3.Engel S.S., Golm G.T., Shapiro D., Davies MJ., Kaufman K.D., Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol. 2013;12:3.Шестакова М.В. Опыт применения ситаглипти-на (первого ингибитора ДПП-4) в лечении сахарного диабета 2 типа в Российской Федерации: результаты наблюдательной программы «Диа-Да». Сахарный диабет. 2010;3:57-60.Shestakova M.V. Experience in using sitagliptin (the first DPP-4 inhibitor) in the treatment of type 2 diabetes in the Russian Federation: the results of the observational Dia-Da program. Sakharny Diabet. 2010;3:57-60. (In Russ).Ким С.С., Ким И.Ч., Ли К.Д., Парк Ч.Х., Ким Й.И., Ли Й.С. и др. Эффективность и безопасность фиксированной комбинации ситаглиптина/мет-формина по сравнению с глимепиридом у пациентов с сахарным диабетом 2 типа: многоцентровое рандомизированное двойное слепое исследование. Эндокринология: новости, мнения, обучение. 2017;4:64-78.Kim S.S., Kim I.Ch., Lee K.D., Park CH.H., Kim I.I., Li YS. et al. Efficacy and safety of the fixed combination of sitagliptin / metformin compared with glimepiride in patients with type 2 diabetes: a multicentre, randomized, double-blind study. Endokrinologia: Novosti, Mnenia, Obuchenie. 2017;4:64-78. (In Russ).Perez-Monteverde A., Seck T., Xu L., Lee M.A., Sisk C.M., Williams-Herman D.E. et al. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes. Int J Clin Pract. 2011 Sep;65(9):930-8.Perez-Monteverde A., Seck T., Xu L., Lee M.A., Sisk C.M., Williams-Herman D.E. et al. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes. Int J Clin Pract. 2011 Sep;65(9):930-8.Reasner C., Olansky L., Seck T.L. et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2011;13:644-652.Reasner C., Olansky L., Seck T.L. et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2011;13:644-652.

The authors declare that there are no conflicts of interest present.